Compare Gilead Sciences, Inc. (GILD) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Snap Inc — how do they compare? Gilead Sciences, Inc. trades at $146.99 (market cap $182.09B), while Snap Inc trades at $5.89 (market cap $9.83B). The key difference: Gilead Sciences, Inc. is far larger — about 18.5× Snap Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Snap Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Snap Inc for 68 Days on average.
| GILD | SNAP | |
|---|---|---|
Market Cap | $182.09B | $9.83B |
Volume | 4,960,247 | 28,532,342 |
Sector | Health | Media |
52-Week High | $155.80 | $9.09 |
52-Week Low | $116.74 | $3.93 |
Typical Hold Time | 111 Days | 68 Days |
Enterprise Value | $205.15B | $11.39B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Snap Inc. (SNAP) trades at $5.865, up 1.12% with a bullish technical signal. Revenue grew to $5.93B in 2025, though net losses persist at -$460M. Recent news highlights AI integration in SPECS glasses via partnerships with NVIDIA and Salesforce. Analyst consensus is mixed with 38% buy ratings and a $7.78 price target.
Outlook: Potential upside exists from AI initiatives and revenue growth, but profitability challenges and high debt ($3.61B) pose risks. The stock's valuation (P/S 1.55) appears reasonable, yet investor caution is warranted amid regulatory pressures and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
